TSCA Fee Authority has become a near-term compliance issue because the statutory authority for EPA to collect Toxic Substances Control Act fees is scheduled to expire on September 30, 2026, unless Congress provides an extension or reauthorization. NAM has called for reauthorization, but its position also ties the funding question to broader changes affecting chemical review, interagency overlap, citizen petitions, and protection of manufacturer-funded data.

For manufacturers, importers, processors, and industrial buyers, the practical concern is not limited to whether a fee invoice is issued. TSCA fees are connected to EPA review capacity, statutory review pathways, and the timing assumptions built into product-development and sourcing files. If the authority lapses, the agency’s ability to recover part of its TSCA implementation costs would be interrupted, and NAM has warned that this could slow review programs that are already time-sensitive.

Why TSCA Fee Authority Matters Before September 30

TSCA Fee Authority And The Budget Share

Under the 2016 Lautenberg Chemical Safety Act, EPA can collect fees to cover up to 25% of the cost of implementing TSCA. That authorization reaches its stated expiration at the end of fiscal year 2026, on September 30, 2026. A Senate short-term funding bill passed in August 2026 included language extending the authority through December 11, 2026, but that short extension did not resolve the longer policy dispute described by NAM.

The significance of the deadline is straightforward: fee revenue is not the whole TSCA budget, but it is a defined part of the cost-recovery structure. NAM’s public concern is that loss of roughly one quarter of program funding could worsen delays in three areas: review of new chemicals or significant new uses, work on chemicals already in commerce, and risk management activity after evaluations. That statement should be treated as a risk claim about administrative capacity, not as proof that every review would stop or that every pending submission would face the same delay.

For approval planning, TSCA Fee Authority matters because companies often build launch, sourcing, and customer-qualification calendars around EPA review milestones. Those calendars are already uncertain where a submission requires additional information, a consent order, a significant new use rule, or coordination with other regulatory obligations. Funding uncertainty adds another variable, but it does not remove the need to make accurate submissions or maintain controlled evidence files.

Scope Documents And Fee Clocks

NAM has also pointed to the status of EPA scope documents for five high-priority substances designated in December 2024: acetaldehyde, acrylonitrile, benzenamine, vinyl chloride, and 4,4’-methylene bis(2-chloroaniline). The Federal Register notice identified these substances as high-priority candidates for risk evaluation activity Federal Register notice. NAM’s concern is that final scope documents were due within six months of designation, and the missed timing affects when certain fee payment clocks begin.

That point is more than procedural. If a fee installment clock depends on publication of a final scope, then delay in the scope document can also delay collection of fees. If collection authority then expires before the relevant payment mechanism is active, EPA may face a cost-recovery gap. The available facts support a narrower conclusion: missed scope deadlines create fee-timing risk. They do not, by themselves, establish how EPA will prioritize every affected risk evaluation.

How Fees Connect To Chemical Approval Files

New Chemical Notices And Exemptions

EPA’s current fee schedule shows the direct cost impact for companies that submit certain Section 5 filings. EPA lists a $37,000 fee for a new chemical notice such as a premanufacture notice, significant new use notice, or microbial commercial activity notice, with an 82.5% discount for qualifying small businesses. EPA also lists a $10,870 fee for certain exemption applications, with an 80% discount for qualifying small business entities EPA TSCA fee schedule.

Those amounts do not decide whether a substance is acceptable for a given use. They are filing-related costs attached to review pathways. The approval risk remains tied to the chemical identity, intended conditions of use, exposure information, hazard information, release scenarios, and EPA’s statutory findings. A company that budgets only for the fee but not for data development, customer communication, and possible use restrictions is treating the filing as an accounting item rather than a regulatory review.

The same distinction applies to buyers. A buyer may not submit the original notice, but its intended application can create pressure on the supplier’s TSCA position. A chemical can remain physically the same while the legal use profile changes; a related discussion of TSCA new use review explains why procurement teams should ask about use limits before commercial activity begins.

Procurement Signals Under Section 5

Companies should avoid assuming that reauthorization would automatically accelerate all reviews, or that a lapse would affect all submissions equally. The available record supports a more cautious planning approach. Funding stability can support program administration, but a submission with incomplete use descriptions or weak exposure information can still face questions. Conversely, a well-prepared file can still be affected by agency workload, statutory timing, or risk-management policy decisions.

A practical approval file should therefore connect the fee event to the business decision that triggered it. A premanufacture notice, significant new use notice, low-volume exemption, low-release and low-exposure exemption, or test marketing exemption should not sit apart from product stewardship records. The same file should identify the intended use, customer class, manufacturing or import route, processing steps, release controls, worker-protection assumptions, and downstream restrictions communicated to sales or procurement.

Documentation Controls For Manufacturers And Buyers

Evidence Files Should Separate Law, Policy, And Forecasts

TSCA Fee Authority reauthorization is a legislative question, while EPA review outcomes remain regulatory decisions made under TSCA. NAM’s recommendations include a durable framework for new chemical reviews, steps to reduce regulatory conflict with OSHA and other agencies, changes to citizen petition provisions, and measures intended to protect manufacturer investments in data and fees from foreign free-riders. Those proposals may influence debate, but they should not be recorded internally as enacted requirements unless Congress acts.

Compliance documentation should separate three categories of information:

• Current legal status: statutory fee authority through September 30, 2026, subject to any enacted extension or reauthorization.
• Current EPA fee schedule: filing fees and small-business discounts applicable to listed notice and exemption types.
• Policy proposals: NAM’s requested reforms, which may or may not appear in final legislation.

This separation helps prevent sales, procurement, and product-development teams from treating a trade association proposal as a binding rule. It also helps prevent the opposite error: ignoring a near-term funding deadline because the company expects Congress to address it. As of September 7, 2026, the deadline remained close enough that pending and planned submissions deserved management attention.

Approval Planning Needs Controlled Assumptions

A controlled planning file should show who owns the submission strategy, which fee-triggering event applies, whether small-business status has been confirmed, what assumptions were made about EPA timing, and how changes in use will be screened. It should also record whether a customer request could create a new significant use question. These records are not a substitute for legal review, but they reduce the chance that a commercial team relies on an outdated status summary.

For readers interested in the importance of disciplined documentation across various fields, a Wills Glaucoma resource underscores that managing source-controlled information is crucial beyond just chemical compliance. In industrial chemical programs, this same principle applies to maintaining accurate fee schedules, submission records, and customer-facing restrictions.

Companies with pending notices or planned submissions should also preserve evidence of the fee schedule relied on at the time of planning. If Congress extends the authority only temporarily, or if later legislation changes fee policy, dated records can help explain why a project budget, customer commitment, or approval forecast used a particular assumption.

NAM’s TSCA Fee Authority Reauthorization Issue

NAM’s reauthorization request is best read as two connected arguments. First, EPA needs continued fee authority to fund a defined portion of TSCA implementation. Second, manufacturers want Congress to use reauthorization to address review predictability, overlapping regulatory demands, petition practice, and compensation concerns tied to data and fee-funded work.

The TSCA Fee Authority debate does not change the immediate compliance task. Manufacturers and buyers still need accurate notice classification, current fee assumptions, clear use descriptions, and documented communication between regulatory, EHS, procurement, and commercial teams. The funding debate may affect timing and policy direction, but approval files should remain grounded in the specific submission pathway and the evidence available for the chemical and its intended use.